Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 95

1.

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.

Fotiou D, Sergentanis TN, Papageorgiou L, Stamatelopoulos K, Gavriatopoulou M, Kastritis E, Psaltopoulou T, Salta S, Van Dreden P, Sangare R, Larsen AK, Terpos E, Elalamy I, Dimopoulos MA, Gerotziafas GT.

Blood Cancer J. 2018 Nov 7;8(11):102. doi: 10.1038/s41408-018-0135-y.

2.

Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.

Salta S, Papageorgiou L, Larsen AK, Van Dreden P, Soulier C, Cokkinos DV, Elalamy I, Gerotziafas GT.

Res Pract Thromb Haemost. 2018 Jul 17;2(4):696-707. doi: 10.1002/rth2.12120. eCollection 2018 Oct.

3.

Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.

Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, Elalamy I, Hoppensteadt D, Gerotziafas GT.

Clin Appl Thromb Hemost. 2018 Oct 8:1076029618806424. doi: 10.1177/1076029618806424. [Epub ahead of print]

PMID:
30296833
4.

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.

Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT.

Oncologist. 2018 Nov;23(11):1372-1381. doi: 10.1634/theoncologist.2017-0530. Epub 2018 Aug 13.

5.

Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.

Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, Salta S, Gerotziafas G, Jing ZC, Elalamy I, Wahl D, Zuily S.

Autoimmun Rev. 2018 Oct;17(10):1011-1021. doi: 10.1016/j.autrev.2018.04.009. Epub 2018 Aug 11. Review.

PMID:
30103045
6.

Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma.

Vathiotis I, Dimakakos EP, Boura P, Ntineri A, Charpidou A, Gerotziafas G, Syrigos K.

Clin Appl Thromb Hemost. 2018 Nov;24(8):1347-1351. doi: 10.1177/1076029618777153. Epub 2018 May 27.

PMID:
29806470
7.

Updated clinical models for VTE prediction in hospitalized medical patients.

Gerotziafas GT, Papageorgiou L, Salta S, Nikolopoulou K, Elalamy I.

Thromb Res. 2018 Apr;164 Suppl 1:S62-S69. doi: 10.1016/j.thromres.2018.02.004. Review.

PMID:
29703486
8.

Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation.

Chaussade E, Hanon O, Boully C, Labourée F, Caillard L, Gerotziafas G, Vidal JS, Elalamy I.

J Nutr Health Aging. 2018;22(1):165-173. doi: 10.1007/s12603-017-0982-4.

PMID:
29300437
9.

Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.

Rousseau A, Van Dreden P, Khaterchi A, Larsen AK, Elalamy I, Gerotziafas GT.

Int J Oncol. 2017 Dec;51(6):1793-1800. doi: 10.3892/ijo.2017.4170. Epub 2017 Oct 20.

PMID:
29075792
10.

Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.

Rousseau A, Larsen AK, Van Dreden P, Sabbah M, Elalamy I, Gerotziafas GT.

Int J Oncol. 2017 Dec;51(6):1747-1756. doi: 10.3892/ijo.2017.4172. Epub 2017 Oct 20.

PMID:
29075790
11.

Modelling of thrombin generation under flow in realistic left anterior descending geometries.

Papadopoulos KP, Gerotziafas GT, Gavaises M.

Med Eng Phys. 2017 Dec;50:50-58. doi: 10.1016/j.medengphy.2017.10.001. Epub 2017 Oct 16.

PMID:
29050805
12.

Thrombin Generation Profile in Patients With Steady State Peripheral Arterial Disease.

Liew A, Failla G, Molinari G, Prior M, Zalunardo B, Pergolini D, Knavs K, Kozak M, Cortelazzo A, Van Dreden P, Elalamy I, Catalano M, Gerotziafas GT.

Clin Appl Thromb Hemost. 2018 Jan;24(1):193-194. doi: 10.1177/1076029617699086. Epub 2017 Aug 30. No abstract available.

PMID:
28854808
13.

Graft Product for Autologous Peripheral Blood Stem Cell Transplantation Enhances Thrombin Generation and Expresses Procoagulant Microparticles and Tissue Factor.

Sidibe F, Spanoudaki A, Vanneaux V, Mbemba E, Larghero J, Van Dreden P, Lotz JP, Elalamy I, Larsen AK, Gerotziafas GT.

Clin Appl Thromb Hemost. 2018 May;24(4):684-690. doi: 10.1177/1076029617715116. Epub 2017 Jul 6.

PMID:
28681632
14.

A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study.

Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, Larsen AK, Elalamy I; COMPASS–CAT Working Group.

Oncologist. 2017 Oct;22(10):1222-1231. doi: 10.1634/theoncologist.2016-0414. Epub 2017 May 26.

15.

Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study.

Gerotziafas GT, Van Dreden P, Mathieu d'Argent E, Lefkou E, Grusse M, Comtet M, Sangare R, Ketatni H, Larsen AK, Elalamy I.

Thromb J. 2017 Mar 28;15:9. doi: 10.1186/s12959-017-0131-7. eCollection 2017.

16.

The Role of Tissue Factor in Cancer-Related Hypercoagulability, Tumor Growth, Angiogenesis and Metastasis and Future Therapeutic Strategies.

Van Dreden P, Εlalamy Ι, Gerotziafas GT.

Crit Rev Oncog. 2017;22(3-4):219-248. doi: 10.1615/CritRevOncog.2018024859. Review.

PMID:
29604900
17.

Rapid detection of D-Dimers with mLabs® whole blood method for venous thromboembolism exclusion. Comparison with Vidas® D-Dimers assay.

Gerotziafas GT, Ray P, Gkalea V, Benzarti A, Khaterchi A, Cast C, Pernet J, Lefkou E, Elalamy I.

Int Angiol. 2016 Dec;35(6):622-628. Epub 2015 Nov 17.

PMID:
26576665
18.

The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.

Sassi M, Chakroun T, Mbemba E, Van Dreden P, Elalamy I, Larsen AK, Gerotziafas GT.

Clin Appl Thromb Hemost. 2017 Mar;23(2):155-163. doi: 10.1177/1076029616665922. Epub 2016 Sep 24.

PMID:
27609342
19.

[Risk of venous thromboembolism in cancer patients: Reality, actuality and perspectives].

Gerotziafas GT, Elalamy I.

Bull Cancer. 2016 Sep;103(9):764-75. doi: 10.1016/j.bulcan.2016.07.001. Epub 2016 Aug 18. Review. French.

PMID:
27481723
20.

A review of the venous thrombotic issues associated with multiple myeloma.

Fotiou D, Gerotziafas G, Kastritis E, Dimopoulos MA, Terpos E.

Expert Rev Hematol. 2016 Jul;9(7):695-706. doi: 10.1080/17474086.2016.1194750. Epub 2016 Jun 8. Review.

PMID:
27232265

Supplemental Content

Loading ...
Support Center